Compare Novartis with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs DR. REDDYS LAB - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS DR. REDDYS LAB NOVARTIS/
DR. REDDYS LAB
 
P/E (TTM) x 493.9 21.6 2,290.7% View Chart
P/BV x 28.7 3.2 887.9% View Chart
Dividend Yield % 1.6 0.7 217.9%  

Financials

 NOVARTIS   DR. REDDYS LAB
EQUITY SHARE DATA
    NOVARTIS
Mar-18
DR. REDDYS LAB
Mar-19
NOVARTIS/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs7582,875 26.4%   
Low Rs5791,888 30.7%   
Sales per share (Unadj.) Rs228.4930.2 24.6%  
Earnings per share (Unadj.) Rs31.7117.4 27.0%  
Cash flow per share (Unadj.) Rs32.8185.8 17.6%  
Dividends per share (Unadj.) Rs10.0020.00 50.0%  
Dividend yield (eoy) %1.50.8 178.1%  
Book value per share (Unadj.) Rs297.1844.4 35.2%  
Shares outstanding (eoy) m24.69166.07 14.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.92.6 114.3%   
Avg P/E ratio x21.120.3 103.9%  
P/CF ratio (eoy) x20.412.8 159.2%  
Price / Book Value ratio x2.22.8 79.8%  
Dividend payout %31.517.0 185.0%   
Avg Mkt Cap Rs m16,505395,496 4.2%   
No. of employees `0000.722.0 3.0%   
Total wages/salary Rs m1,44533,562 4.3%   
Avg. sales/employee Rs Th8,441.37,032.8 120.0%   
Avg. wages/employee Rs Th2,163.61,527.9 141.6%   
Avg. net profit/employee Rs Th1,173.1887.7 132.1%   
INCOME DATA
Net Sales Rs m5,639154,482 3.7%  
Other income Rs m1,7183,375 50.9%   
Total revenues Rs m7,357157,857 4.7%   
Gross profit Rs m-6331,782 -0.2%  
Depreciation Rs m2511,348 0.2%   
Interest Rs m55889 6.2%   
Profit before tax Rs m1,57522,920 6.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0438 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7923,858 20.5%   
Profit after tax Rs m78419,500 4.0%  
Gross profit margin %-1.120.6 -5.4%  
Effective tax rate %50.316.8 298.6%   
Net profit margin %13.912.6 110.1%  
BALANCE SHEET DATA
Current assets Rs m9,522111,101 8.6%   
Current liabilities Rs m3,29658,973 5.6%   
Net working cap to sales %110.433.7 327.2%  
Current ratio x2.91.9 153.3%  
Inventory Days Days3779 46.1%  
Debtors Days Days2894 30.2%  
Net fixed assets Rs m46101,245 0.0%   
Share capital Rs m123830 14.9%   
"Free" reserves Rs m7,213139,406 5.2%   
Net worth Rs m7,336140,236 5.2%   
Long term debt Rs m022,000 0.0%   
Total assets Rs m11,105224,656 4.9%  
Interest coverage x29.526.8 110.1%   
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x0.50.7 73.8%   
Return on assets %7.69.1 83.2%  
Return on equity %10.713.9 76.8%  
Return on capital %22.214.9 148.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6188,673 0.1%   
Fx outflow Rs m3,63019,104 19.0%   
Net fx Rs m-3,57069,569 -5.1%   
CASH FLOW
From Operations Rs m1,61028,704 5.6%  
From Investments Rs m687-7,727 -8.9%  
From Financial Activity Rs m-2,677-21,326 12.6%  
Net Cashflow Rs m-380-314 120.9%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 5.4 37.0%  
FIIs % 1.6 35.3 4.5%  
ADR/GDR % 0.0 18.5 -  
Free float % 21.5 15.3 140.5%  
Shareholders   41,647 75,885 54.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   IPCA LABS  GSK PHARMA  PANACEA BIOTECH  ORCHID PHARMA LTD  SANOFI INDIA  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 19, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS